PRD_000204
Vancomycin
PRD_000204 is described in the Biologically Interesting Molecule Reference Dictionary (BIRD).
The representative PDB ID is 1AA5.
Chemical Component Summary | |
---|---|
Name | Vancomycin |
Identifiers | n/a |
Formula | C66 H75 Cl2 N9 O24 |
Molecular Weight | 1,449.254 |
Type | PEPTIDE-LIKE |
Isomeric SMILES | C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2Oc3c4cc5cc3Oc6ccc(cc6Cl)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7c8ccc(c(c8)-c9c(cc(cc9O)O)[C@H](NC(=O)[C@H]([C@@H](c1ccc(c(c1)Cl)O4)O)NC7=O)C(=O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)CO)O)O)(C)N)O |
InChI | InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1 |
InChIKey | MYPYJXKWCTUITO-LYRMYLQWSA-N |
Composition | Polymer Sequences: MLU-OMZ-ASN-GHP-GHP-OMY-3FG-BGC-RER |
BIRD class | ANTIBIOTIC |
Represented As | POLYMER |
Compound Details | n/a |
Description | n/a |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 176 |
Chiral Atom Count | 18 |
Bond Count | 185 |
Aromatic Bond Count | 30 |
Drug Info: DrugBank
DrugBank ID | DB00512 |
---|---|
Name | Vancomycin |
Groups | approved |
Description | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196]. |
Synonyms |
|
Brand Names |
|
Indication | Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections.[L41529] Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of _Clostridium difficile_-associated diarrhea and for enterocolitis caused by _Staphylococcus aureus_ (including methicillin-resistant strains).[L41534] |
Categories |
|
ATC-Code |
|
CAS number | 1404-90-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan | - | unknown | ligand |
Serum albumin | MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA... | unknown | substrate |
alpha1-acid glycoprotein | MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAF... | unknown | substrate |
Histamine H1 receptor | MSLPNTSSASEDKMCEGNRTAMASPQLLPLVVVLSSISLVTVGLNLLVLY... | unknown | substrate |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL262777 |
PubChem | 14969 |
ChEMBL | CHEMBL262777 |
ChEBI | CHEBI:28001 |